Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an
immune response that will kill cancer cells. Interleukin-2 and interferon gamma may enhance
the effectiveness of graft-versus-host disease to kill cancer cells.
PURPOSE: Randomized phase III trial to determine the effectiveness of graft-versus-host
disease in treating patients who have recurrent or refractory lymphoma or Hodgkin's disease .
Phase:
Phase 3
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins